| Laura L Levin, MD | |
|
800 Meadows Rd, Boca Raton, FL 33486-2304 | |
| (561) 955-7100 | |
| Not Available |
| Full Name | Laura L Levin |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 15 Years |
| Location | 800 Meadows Rd, Boca Raton, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629205398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD455265 (Pennsylvania) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | ME147090 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Temple University Hospital | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Temple Faculty Practice Plan Inc | 0345588711 | 1063 |
News Archive
Trust for America's Health commends the Childhood Obesity Task Force's report, Solving the Problem of Childhood Obesity Within a Generation, which includes proposed recommendations for reducing the rate of childhood obesity from 17% to 5% by 2030. The report includes a total of 70 recommendations for specific action steps, many of which can be implemented right away and are minimal or no-cost.
Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
› Verified 8 days ago
| Entity Name | Diagnostic Imaging Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093786410 PECOS PAC ID: 1254231087 Enrollment ID: O20040109000455 |
News Archive
Trust for America's Health commends the Childhood Obesity Task Force's report, Solving the Problem of Childhood Obesity Within a Generation, which includes proposed recommendations for reducing the rate of childhood obesity from 17% to 5% by 2030. The report includes a total of 70 recommendations for specific action steps, many of which can be implemented right away and are minimal or no-cost.
Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
› Verified 8 days ago
| Entity Name | Fox Chase Cancer Center Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396019444 PECOS PAC ID: 8123289550 Enrollment ID: O20120412000054 |
News Archive
Trust for America's Health commends the Childhood Obesity Task Force's report, Solving the Problem of Childhood Obesity Within a Generation, which includes proposed recommendations for reducing the rate of childhood obesity from 17% to 5% by 2030. The report includes a total of 70 recommendations for specific action steps, many of which can be implemented right away and are minimal or no-cost.
Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
› Verified 8 days ago
| Entity Name | Temple Faculty Practice Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881176949 PECOS PAC ID: 0345588711 Enrollment ID: O20190208002623 |
News Archive
Trust for America's Health commends the Childhood Obesity Task Force's report, Solving the Problem of Childhood Obesity Within a Generation, which includes proposed recommendations for reducing the rate of childhood obesity from 17% to 5% by 2030. The report includes a total of 70 recommendations for specific action steps, many of which can be implemented right away and are minimal or no-cost.
Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura L Levin, MD Po Box 919336, Miami, FL 32891-0001 Ph: (800) 841-4236 | Laura L Levin, MD 800 Meadows Rd, Boca Raton, FL 33486-2304 Ph: (561) 955-7100 |
News Archive
Trust for America's Health commends the Childhood Obesity Task Force's report, Solving the Problem of Childhood Obesity Within a Generation, which includes proposed recommendations for reducing the rate of childhood obesity from 17% to 5% by 2030. The report includes a total of 70 recommendations for specific action steps, many of which can be implemented right away and are minimal or no-cost.
Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
› Verified 8 days ago
Dr. Anastasia Frances Barron, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St Ste 1d, Boca Raton, FL 33486 Phone: 312-724-8477 | |
Dr. Ira J Braunschweig, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St, Suite 1c, Boca Raton, FL 33486 Phone: 561-447-9341 Fax: 561-447-9352 | |
Dr. Craig Kolodziej, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 951 Nw 13th St, Suite 1c, Boca Radiology Group, Boca Raton, FL 33486 Phone: 561-447-9341 | |
Surya Vaidyanathan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Meadows Rd, Suite 1c, Boca Raton, FL 33486 Phone: 561-447-9341 | |
Dr. Thomas Jose Eluvathingal, M.D.,MB;BS Radiology Medicare: Accepting Medicare Assignments Practice Location: 3848 Fau Blvd Ste 305, Boca Raton, FL 33431 Phone: 561-455-3627 Fax: 305-243-4613 | |
Dr. Sabrina Yvette Saida, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Meadows Rd, Boca Raton, FL 33486 Phone: 561-447-9341 Fax: 561-447-9352 | |
Dr. Edward Victor Grayson, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3435 Windsor Pl, Boca Raton, FL 33496 Phone: 561-926-3230 |